Deciphera Pharmaceutical News Today

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

KALA BIO (NASDAQ:KALA – Get Free Report) and Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability. Institutional and Insider Ownership 24.0% of KALA […]

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Free Report) – Zacks Research issued their FY2026 earnings per share estimates for Deciphera Pharmaceuticals in a research note issued to investors on Tuesday, February 27th. Zacks Research analyst A. Chakraborty anticipates that the company will post earnings per share of ($1.25) for the year. The consensus estimate for Deciphera […]

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Free Report) – Equities researchers at Zacks Research issued their FY2026 earnings per share estimates for Deciphera Pharmaceuticals in a research report issued on Tuesday, February 27th. Zacks Research analyst A. Chakraborty anticipates that the company will post earnings of ($1.25) per share for the year. The consensus estimate for […]

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Free Report) – Research analysts at HC Wainwright raised their Q1 2024 EPS estimates for Deciphera Pharmaceuticals in a report issued on Wednesday, February 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.63) per share for the quarter, up from their previous estimate […]

Last week, you might have seen that Deciphera Pharmaceuticals, Inc. ( NASDAQ:DCPH ) released its annual result to the...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Is Deciphera Pharmaceuticals' Stock Undervalued? A Comprehensive Analysis of Its Market Value

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) – Equities research analysts at SVB Leerink cut their Q2 2023 EPS estimates for shares of Deciphera Pharmaceuticals in a research note issued to investors on Wednesday, May 3rd. SVB Leerink analyst A. Berens now forecasts that the company will earn ($0.65) per share for the quarter, down […]

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) – Research analysts at SVB Leerink decreased their FY2025 earnings estimates for shares of Deciphera Pharmaceuticals in a research note issued on Tuesday, April 25th. SVB Leerink analyst A. Berens now forecasts that the company will post earnings per share of $0.26 for the year, down from their […]